ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

23 окт 2023 16:01:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 окт 2023 16:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

18 окт 2023 21:16:45 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Proposed Public Offering of Common Stock

17 окт 2023 16:02:14 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease

16 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

14 окт 2023 16:30:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 окт 2023 17:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

09 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023

05 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 сен 2023 17:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in September

31 авг 2023 09:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 авг 2023 17:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

03 авг 2023 16:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

31 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

27 июл 2023 17:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 июл 2023 17:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

12 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

06 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts

21 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 июн 2023 17:00:00 Источник Nasdaq GlobeNewswire